Interaction between plasma phospholipid odd‑chain fatty acids and GAD65 autoantibodies on the incidence of adult‑onset diabetes: the EPIC‑InterAct case–cohort study
Autor/a
Otros/as autores/as
Fecha de publicación
2023-06Resumen
Aims/hypothesis Islet autoimmunity may progress to adult-onset diabetes. We investigated whether circulating odd-chain
fatty acids (OCFA) 15:0 and 17:0, which are inversely associated with type 2 diabetes, interact with autoantibodies against
GAD65 (GAD65Ab) on the incidence of adult-onset diabetes.
Methods We used the European EPIC-InterAct case–cohort study including 11,124 incident adult-onset diabetes cases and
a subcohort of 14,866 randomly selected individuals. Adjusted Prentice-weighted Cox regression estimated HRs and 95%
CIs of diabetes in relation to 1 SD lower plasma phospholipid 15:0 and/or 17:0 concentrations or their main contributor,
dairy intake, among GAD65Ab-negative and -positive individuals. Interactions between tertiles of OCFA and GAD65Ab
status were estimated by proportion attributable to interaction (AP).
Results Low concentrations of OCFA, particularly 17:0, were associated with a higher incidence of adult-onset diabetes in
both GAD65Ab-negative (HR 1.55 [95% CI 1.48, 1.64]) and GAD65Ab-positive (HR 1.69 [95% CI 1.34, 2.13]) individuals. The combination of low 17:0 and high GAD65Ab positivity vs high 17:0 and GAD65Ab negativity conferred an HR
of 7.51 (95% CI 4.83, 11.69), with evidence of additive interaction (AP 0.25 [95% CI 0.05, 0.45]). Low dairy intake was
not associated with diabetes incidence in either GAD65Ab-negative (HR 0.98 [95% CI 0.94, 1.02]) or GAD65Ab-positive
individuals (HR 0.97 [95% CI 0.79, 1.18]).
Conclusions/interpretation Low plasma phospholipid 17:0 concentrations may promote the progression from GAD65Ab
positivity to adult-onset diabetes.
Tipo de documento
Artículo
Versión del documento
Versión publicada
Lengua
Inglés
Materias (CDU)
579 - Microbiología
616.3 - Patología del aparato digestivo. Odontología
Palabras clave
Páginas
12 p.
Publicado por
Springer Nature
Publicado en
Diabetologia, 2023, 66: 1460-1471
Número del acuerdo de la subvención
info:eu-repo/grantAgreement/EU/H2020/LSHM_CT_2006_037197
info:eu-repo/grantAgreement/NIH/DK-26190 (CSH)
info:eu-repo/grantAgreement/NIH/DK-26190 (CSH)
info:eu-repo/grantAgreement/Västerbotten County Council, UU i MRC/ MC_UU_12015/1 (NJW)
info:eu-repo/grantAgreement/SRCH/FORTE 2018-00337
info:eu-repo/grantAgreement/NNF/NNF19OC0057274
info:eu-repo/grantAgreement/SRC/2018- 03035
info:eu-repo/grantAgreement/SDF/DIA2022-735
info:eu-repo/grantAgreement/MINECO/ISCIII i ESF/CPII20/00009
info:eu-repo/grantAgreement/MIER i GCDR/82DZD03D03
info:eu-repo/grantAgreement/MRC Epidemiology Unit/MC_UU_00006/1
info:eu-repo/grantAgreement/MRC Epidemiology Unit/MC_UU_00006/3
info:eu-repo/grantAgreement/NIH i CBRC/NIHR203312
Este ítem aparece en la(s) siguiente(s) colección(ones)
Derechos
© L'autor/a
Excepto si se señala otra cosa, la licencia del ítem se describe como http://creativecommons.org/licenses/by/4.0/